Immunocore (NASDAQ:IMCR) Sets New 12-Month Low at $32.55

Shares of Immunocore Holdings plc (NASDAQ:IMCR) hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as $32.55 and last traded at $32.72, with a volume of 45718 shares changing hands. The stock had previously closed at $34.26.

Wall Street Analyst Weigh In

A number of research firms have recently commented on IMCR. Needham & Company LLC reaffirmed a “buy” rating and issued a $81.00 price target on shares of Immunocore in a report on Friday, August 9th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Immunocore in a research report on Monday. HC Wainwright reiterated a “buy” rating and issued a $100.00 target price on shares of Immunocore in a research report on Wednesday, August 28th. JPMorgan Chase & Co. dropped their price target on Immunocore from $70.00 to $66.00 and set an “overweight” rating for the company in a research note on Wednesday, July 10th. Finally, Oppenheimer reiterated an “outperform” rating and set a $89.00 target price (up from $87.00) on shares of Immunocore in a report on Friday, August 9th. One investment analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $80.70.

Immunocore Trading Down 3.9 %

The company has a current ratio of 5.17, a quick ratio of 5.15 and a debt-to-equity ratio of 1.31. The stock has a market capitalization of $1.65 billion, a P/E ratio of -26.57 and a beta of 0.73. The company has a 50-day moving average price of $37.51 and a 200 day moving average price of $48.16.

Immunocore (NASDAQ:IMCR) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.25. Immunocore had a negative net margin of 19.16% and a negative return on equity of 14.68%. The firm had revenue of $75.40 million for the quarter, compared to the consensus estimate of $74.58 million. During the same quarter in the previous year, the firm earned ($0.37) EPS. The company’s quarterly revenue was up 26.2% compared to the same quarter last year. On average, research analysts forecast that Immunocore Holdings plc will post -1.79 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Immunocore

Large investors have recently bought and sold shares of the company. Fiera Capital Corp lifted its stake in shares of Immunocore by 24.6% in the 4th quarter. Fiera Capital Corp now owns 846,787 shares of the company’s stock valued at $57,852,000 after purchasing an additional 166,988 shares during the last quarter. Robeco Institutional Asset Management B.V. acquired a new stake in shares of Immunocore during the fourth quarter valued at about $5,064,000. Trexquant Investment LP raised its stake in shares of Immunocore by 6.5% in the 4th quarter. Trexquant Investment LP now owns 28,545 shares of the company’s stock valued at $1,950,000 after acquiring an additional 1,746 shares during the period. Assetmark Inc. lifted its holdings in shares of Immunocore by 63.3% in the 4th quarter. Assetmark Inc. now owns 17,980 shares of the company’s stock worth $1,228,000 after acquiring an additional 6,969 shares during the last quarter. Finally, Hsbc Holdings PLC acquired a new position in shares of Immunocore in the 4th quarter worth approximately $4,450,000. 84.50% of the stock is currently owned by hedge funds and other institutional investors.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.